[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635391":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":29,"overallOfficials":11,"centralContacts":35,"locations":41,"responsibleParty":115,"collaborators":11,"id":117,"slug":11,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":11,"enrollmentInfo":125,"targetDuration":11,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Palvella Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13,15],{"measure":10,"description":11,"timeFrame":12},"Incidence of Treatment-Emergent Adverse Events",null,"3 months",{"measure":14,"description":11,"timeFrame":12},"Overall Angiokeratoma Investigator Global Assessment (AK-IGA)",{"measure":16,"description":11,"timeFrame":12},"Overall Patient Global Impression of Change (PGI-C)",{"allocation":18,"interventionModel":19,"interventionModelDescription":11,"primaryPurpose":20,"observationalModel":11,"timePerspective":11,"maskingInfo":21},"NA","SINGLE_GROUP","TREATMENT",{"masking":22,"maskingDescription":11,"whoMasked":11},"NONE",[24],{"label":25,"type":26,"description":11,"interventionNames":27},"Open label","EXPERIMENTAL",[28],"Drug: PTX-022",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":11},"DRUG","PTX-022","topical administration of PTX-022",[25],[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Emily Cook","CONTACT","267-738-6366","emily.cook@palvellatx.com",[42,64,83,98],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Unified Health","NOT_YET_RECRUITING","Sherman Oaks","California","91403","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-118.44925,34.15112,{"lat":54,"lon":53},[57,61],{"name":58,"role":38,"phone":59,"phoneExt":11,"email":60},"Jamie Goodnight","(833) 525-CURA (2872)","jgoodnight@curaclinicalresearch.com",{"name":62,"role":63,"phone":11,"phoneExt":11,"email":11},"Michael Lin, MD","PRINCIPAL_INVESTIGATOR",{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":48,"countryCode":49,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Cleaver Medical Group","RECRUITING","Dawsonville","Georgia","30534",{"type":51,"coordinates":71},[72,73],-84.11908,34.42121,{"lat":73,"lon":72},[76,81],{"name":77,"role":38,"phone":78,"phoneExt":79,"email":80},"Dana Anderson","770.800.3455","1014","danderson@cleavermedicalgroup.com",{"name":82,"role":63,"phone":11,"phoneExt":11,"email":11},"Nathan Cleaver, MD",{"facility":84,"status":44,"city":85,"state":86,"zip":87,"country":48,"countryCode":49,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Vividia Dermatology","Las Vegas","Nevada","89148",{"type":51,"coordinates":89},[90,91],-115.13722,36.17497,{"lat":91,"lon":90},[94,97],{"name":95,"role":38,"phone":11,"phoneExt":11,"email":96},"Graham Lichtman, MD","graham.litchman@gmail.com",{"name":95,"role":63,"phone":11,"phoneExt":11,"email":11},{"facility":99,"status":66,"city":100,"state":101,"zip":102,"country":48,"countryCode":49,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Epiphany Dermatology","Southlake","Texas","76092",{"type":51,"coordinates":104},[105,106],-97.13418,32.94124,{"lat":106,"lon":105},[109,113],{"name":110,"role":38,"phone":111,"phoneExt":11,"email":112},"Moraima Avalos","(214) 884 - 7558","chintan@stryderesearch.com",{"name":114,"role":63,"phone":11,"phoneExt":11,"email":11},"Todd Plott, MD",{"type":116,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100635391",false,"NCT07552077","A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)","LOTU","Inclusion Criteria:\n\n* Participants must be 6 years or older\n* Diagnosed with angiokeratoma\n* Able and willing to comply with all protocol-related activities\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Any significant concurrent condition that could adversely affect participation\n* Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications or to PTX-022\n* Patients deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, including adherence to study drug administration and other protocol-required activities","ALL","6 Years",{"count":126,"type":127},15,"ESTIMATED","INTERVENTIONAL",[130],"PHASE2","The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas",[133],"Angiokeratomas",[135],"angiokeratoma","2026-04-20",{"date":138,"type":139},"2026-04-27","ACTUAL",{"date":141,"type":127},"2026-04",{"date":143,"type":127},"2027-09",{"name":5,"class":6},4]